Shandong Jincheng Pharmaceutical Group Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shandong Jincheng Pharmaceutical Group Co., Ltd. was established in 2004 and headquartered in Zibo City, Shandong Province. It was listed on the Shenzhen Stock Exchange Growth Enterprise Board (stock code SZ300233) in 2011. It is a national high-tech enterprise with over 30 participating holding companies worldwide. Mainly engaged in the research and development, production, and sales of pharmaceutical intermediates, raw materials, pharmaceutical preparations, large health products, and synthetic biology products, as well as CMO/CDMO services for pharmaceutical intermediates and raw materials. It is a globally renowned production and research base for cephalosporin side chain intermediates and biological fermentation raw materials such as glutathione, a well-known domestic manufacturer of anti infection and gynecological preparations, and has a rich range of cephalosporin antibiotics and gynecological full life cycle products in China. It is an emerging and internationalized domestic pharmaceutical and health industry group that integrates research, production, and sales throughout the entire industry chain. The company adheres to the strategic development orientation of basing itself on the big medicine and expanding the big health. It now has anti infection, gynecology, anti-virus, chronic disease, paediatrics, hormone and immune regulation, liver disease and other therapeutic products. It has more than 80 drug and health care product registration approvals and supporting ten major production bases in Beijing, Shanghai, Guangzhou and Shandong, including chemical raw materials, injections, tablets, capsules, soft capsules, powders, sprays, creams, etc. We have created multiple well-known brand products in the industry, including Jincheng Cephalosporin Intermediates, Jinpin Antibiotics Series, Longyi Gynecology Series, Glutathione API and Health Products Series. Three injection products have won the national centralized procurement of drugs, and more than ten products have passed consistency evaluations. The company has established long-term cooperative relationships with hundreds of pharmaceutical companies around the world, forming a global market layout with the domestic market as the main body and the mainstream markets in Europe, America, and India as the main export destinations, radiating into the markets of Japan, South Korea, and ASEAN. It provides medical and health products to more than 30 countries and regions worldwide, as well as more than 3000 medical institutions and chain pharmacies in China. Every year, hundreds of millions of patients regain their health by using Jincheng Pharmaceutical's products. The company has won over 300 honors, including the National Science and Technology Progress Award and the Best ChiNext Listed Company. It has been successfully selected for the FTSE Russell Index and has been ranked among the "Double Hundred" of China's pharmaceutical industry and China's pharmaceutical industry. It is moving forward with the development vision of becoming an innovative leading enterprise in the pharmaceutical and health industry. In the future, Jincheng Pharmaceutical will adhere to the overall strategy of "focusing on the main business, aggregating resources, and uniting innovation", with high-quality development as the lead, meeting customer and clinical needs as the center, focusing on high-end medical products, high threshold characteristic raw materials and synthetic biology products, high-level generic drugs and improved innovative drugs, expanding CMO/CDMO business, actively exploring the field of innovative drugs, enhancing the innovation system of the entire industry chain, and innovating new models of pharmaceutical research and development, Strive to build the enterprise into a globally renowned and nationally leading innovative pharmaceutical and health group. |
| Headquarter | Zibo |
| Establish Date | 1/12/2004 |
| Listed Code | 300233.SZ |
| Listed Date | 6/22/2011 |
| Chairman | Zhao Yeqing. |
| CEO | Li Jiaquan. |
| Website | www.jinchengpharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
